Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Discover a study that raises important concerns about the long-term mental health of individuals with resolved HBV infection.

Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...

Some victims of the infected blood scandal will die before they receive compensation and the current number of people who ...